Campaign to urge UCLA to make a prostate cancer drug affordable!

In March 2018, UAEM students launched a campaign to press the University of California (UCLA) to drop its patent claim in India on Xtandi, a life-saving prostate cancer medicine (brand name Xtandi) which was developed on its campus with public funds.

Make Medicine for People Not for Profit! #TakeBackXtandi

Join us to urge UCLA and the University of California system to drop the patent claim in India on a life-saving prostate cancer drug developed on campus with tax-payer funds!

Visit UAEM UCLA chapter new Xtnadi website here.

Checkout a short Xtandi campaign video clip here.

We’re in the media:

1. STAT NEWS: Students push UCLA to improve access to drug developed by its researchers

2. ALTERNET: Why is UCLA Doing Big Pharma’s Dirty Work? 
3. THE WIRE INDIA: US Students urge UCLA to Drop Proxy Patent Battle for Cancer Drug in India 

To learn more or to get engaged please email:

CC BY-NC-SA 4.0 This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Comments are closed.